Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ASP 8497

Known as: ASP-8497, ASP8497 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
(2S,4S)-4-Fluoro-1-({[4-methyl-1-(methylsulfonyl)piperidin-4-yl]amino}acetyl)pyrrolidine-2-carbonitrile monofumarate (ASP8497) is… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2009
2009
Several combination therapies have been investigated in an effort to achieve and maintain glycemic control in patients with type… Expand
2009
2009
The present study investigated the antidiabetic effects of the dipeptidyl peptidase (DPP)-IV inhibitors ASP8497 and vildagliptin… Expand
2009
2009
Gastrointestinal hormone glucagon-like peptide-1 (GLP-1) has a potent glucose-dependent insulinotropic effect and is rapidly… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2009
2009
UNLABELLED Sulfonylureas promote insulin secretion and potently lower blood glucose levels, however, they induce hypoglycemia and… Expand
2008
2008
Dipeptidyl peptidase-IV (DPP-IV) is the primary inactivator of glucoregulatory incretin hormones, and DPP-IV inhibitors are… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2008
2008
Dipeptidyl peptidase (DPP)-IV is involved in the inactivation of glucagon-like peptide-1 (GLP-1), a potent insulinotropic peptide… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2008
2008
Dipeptidyl peptidase (DPP)-IV inhibitors are expected to become a useful new class of antidiabetic agent. The aim of the present… Expand